Reduction of interstitial fluid pressure after TNF-alpha treatment of three human melanoma xenografts.

Tumour necrosis factor-alpha (TNF-alpha) reduced the interstitial fluid pressure (IFP) to 54-64% (P < 0.05) and the mean arterial blood pressure (MABP) to 70% (P < 0.01) of control values after 5 h in three human melanoma tumour lines transplanted to nude mice.

[1]  E. Rofstad,et al.  Interstitial fluid pressure in human melanoma xenografts. Relationship to fractional tumor water content, tumor size, and tumor volume-doubling time. , 1995, Acta oncologica.

[2]  R K Jain,et al.  Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse. , 1992, Cancer research.

[3]  N. Renard,et al.  High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  W. Fiers,et al.  The toxic effects of tumor necrosis factor in vivo and their prevention by cyclooxygenase inhibitors. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[5]  R. Skalak,et al.  Time-dependent behavior of interstitial fluid pressure in solid tumors: implications for drug delivery. , 1995, Cancer research.

[6]  R. Jain,et al.  Dexamethasone reduces the interstitial fluid pressure in a human colon adenocarcinoma xenograft. , 1993, Cancer research.

[7]  R K Jain,et al.  Interstitial hypertension in superficial metastatic melanomas in humans. , 1991, Cancer research.

[8]  R. Jain,et al.  Effect of angiotensin II induced hypertension on tumor blood flow and interstitial fluid pressure. , 1993, Cancer research.

[9]  D. Longo,et al.  Interstitial pressure of subcutaneous nodules in melanoma and lymphoma patients: changes during treatment. , 1993, Cancer research.

[10]  F. Buchegger,et al.  Tumor‐necrosis factor can enhance radio‐antibody uptake in human colon carcinoma xenografts by increasing vascular permeability , 1993, International journal of cancer.

[11]  A. Maraveyas,et al.  Effect of tumour necrosis factor on the uptake of specific and control monoclonal antibodies in a human tumour xenograft model. , 1995, British Journal of Cancer.

[12]  A. Asher,et al.  Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. , 1987, Journal of immunology.

[13]  Rakesh K. Jain,et al.  Transport Phenomena in Tumors , 1994 .

[14]  Kevin J. Tracey,et al.  Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia , 1987, Nature.

[15]  N. Cascinelli,et al.  Treatment of primary or relapsing limb cancer by isolation perfusion with high‐dose alpha‐tumor necrosis factor, gamma‐interferon, and melphalan , 1994, Cancer.

[16]  R K Jain,et al.  Pharmacologic modification of tumor blood flow and interstitial fluid pressure in a human tumor xenograft: network analysis and mechanistic interpretation. , 1995, Microvascular research.

[17]  J. Adams,et al.  hypotension: Implications for the involvement of nitric oxide , 2022 .